Before you go, check out Dr. Lawrence Rosenberg's reflection on what "excellence" actually means in health care. He is the ...

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

Novo Nordisk NVO -1.23% Get Free Report has outperformed the market over the past 5 years by 1.33% on an annualized basis producing an average annual return of 15.96%. Currently, Novo Nordisk has a ...

ISLAMABAD: Pakistan can significantly reduce national health expenditure by controlling obesity by creating awareness and ...

Lupin Limited has received approval from the United States Food and Drug Administration for its Abbreviated New Drug ...

Denmark is investing 80 million euro in a quantum computing project intended to bring a commercial-grade system to the Nordic ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...